Publications by authors named "Hanspeter Gerber"

Claim this Profile
H
Homogeneous antibody-drug conjugates with dual payloads: potential, methods and considerations.
Miao Wen, Abigail Yu, Young Park, Daniel Calarese, Hans-Peter Gerber

MAbs· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Anti-FRα Antibody-Drug Conjugate Luveltamab Tazevibulin Demonstrates Efficacy in Non-Small Cell Lung Cancer Preclinical Models and Induces Immunogenic Cell Death.
Robert Yuan, Andrew McGeehan, Sihong Zhou, Christine Cheng, Mark Armanini, Hans-Peter Gerber

Mol Cancer Ther· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic index improvement of antibody-drug conjugates.
Hans-Peter Gerber, Sanjeev Gangwar, Alison Betts

MAbs· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TCR mimic compounds for pHLA targeting with high potency modalities in oncology.
Hans-Peter Gerber, Leonard G Presta

Front Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-Extra Domain B Splice Variant of Fibronectin Antibody-Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade.
Andrea T Hooper, Kimberly Marquette, Chao-Pei Betty Chang, Jonathon Golas, Sadhana Jain, Hans-Peter Gerber

Mol Cancer Ther· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NOTCH3-targeted antibody drug conjugates regress tumors by inducing apoptosis in receptor cells and through transendocytosis into ligand cells.
Kenneth G Geles, Yijie Gao, Andreas Giannakou, Latha Sridharan, Ting-Ting Yamin, Hans-Peter Gerber

Cell Rep Med· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia.
Yoon-Chi Han, Jennifer Kahler, Nicole Piché-Nicholas, Wenyue Hu, Stephane Thibault, Hans-Peter Gerber

Clin Cancer Res· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PF-06804103, A Site-specific Anti-HER2 Antibody-Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers.
Edmund I Graziani, Matthew Sung, Dangshe Ma, Bitha Narayanan, Kimberly Marquette, Hans-Peter Gerber

Mol Cancer Ther· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Antigenic Targets.
Hans-Peter Gerber, Leah V Sibener, Luke J Lee, Marvin H Gee

Trends Cancer· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intracellular targets as source for cleaner targets for the treatment of solid tumors.
Hans-Peter Gerber, Leah V Sibener, Luke J Lee, Marvin Gee

Biochem Pharmacol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in mice.
Timothy S Fisher, Andrea T Hooper, Justin Lucas, Tracey H Clark, Allison K Rohner, Hans-Peter Gerber

Cancer Immunol Immunother· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1).
Matthew Sung, Xingzhi Tan, Bingwen Lu, Jonathan Golas, Christine Hosselet, Hans-Peter Gerber

Mol Cancer Ther· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detecting expression of 5T4 in CTCs and tumor samples from NSCLC patients.
Steven R Pirie-Shepherd, Cory Painter, Pamela Whalen, Pamela Vizcarra, Marc Roy, Hans-Peter Gerber

PLoS One· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liver Microvascular Injury and Thrombocytopenia of Antibody-Calicheamicin Conjugates in Cynomolgus Monkeys-Mechanism and Monitoring.
Magali Guffroy, Hadi Falahatpisheh, Kathleen Biddle, John Kreeger, Leslie Obert, Hans-Peter Gerber

Clin Cancer Res· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanisms of Resistance to Antibody-Drug Conjugates.
Frank Loganzo, Matthew Sung, Hans-Peter Gerber

Mol Cancer Ther· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Next-Generation Antibody-Drug Conjugates (ADCs) for Cancer Therapy.
Jagath Reddy Junutula, Hans-Peter Gerber

ACS Med Chem Lett· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer.
Adam R Root, Wei Cao, Bilian Li, Peter LaPan, Caryl Meade, Hans-Peter Gerber

Antibodies (Basel)· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect?
Hans-Peter Gerber, Puja Sapra, Frank Loganzo, Chad May

Biochem Pharmacol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies.
Boris Shor, Hans-Peter Gerber, Puja Sapra

Mol Immunol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions.
Marc Damelin, Alexander Bankovich, Albert Park, Jorge Aguilar, Wade Anderson, Hans-Peter Gerber

Clin Cancer Res· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments.
Frank Loganzo, Xingzhi Tan, Matthew Sung, Guixian Jin, Jeremy S Myers, Hans-Peter Gerber

Mol Cancer Ther· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in patient-derived tumor xenografts: from target identification to predicting clinical response rates in oncology.
Edward Rosfjord, Judy Lucas, Gang Li, Hans-Peter Gerber

Biochem Pharmacol· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A general approach to site-specific antibody drug conjugates.
Feng Tian, Yingchun Lu, Anthony Manibusan, Aaron Sellers, Hon Tran, Hans-Peter Gerber

Proc Natl Acad Sci U S A· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach.
Nahor Haddish-Berhane, Dhaval K Shah, Dangshe Ma, Mauricio Leal, Hans-Peter Gerber

J Pharmacokinet Pharmacodyn· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics.
Hans-Peter Gerber, Frank E Koehn, Robert T Abraham

Nat Prod Rep· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis